Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01370109 · ClinicalTrials.gov registry record
Cardiovascular Effects of Sunitinib Therapy (CREST)
A clinical trial of Renal Cell Carcinoma 4, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- 98
- Enrollment target
- 1
- Study location
NCT01370109 is a study of Renal Cell Carcinoma 4 that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 98 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01370109, a study of Renal Cell Carcinoma 4, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- 98 participants
- Enrollment target
- 1
- Study location
Study Summary
Tyrosine kinase inhibitors such as sunitinib are used in the treatment of renal cell carcinoma and have significant off-target effects with cardiac toxicity and resultant ventricular cardiac dysfunction being a major concern. However, the mechanisms of these effects in humans remains poorly defined, as are the clinical methods to risk stratify and identify patients who will ultimately suffer from cardiac dysfunction. The goal of this multi-center study is to characterize the cardiovascular measures of cardiac function; 2) comprehensive measures of arterial function and left ventricular afterload; 3) biomarkers reflective of the pathophysiologic alterations. Through this work, the investigators will translate our basic understanding of sunitinib cardiotoxicity to humans and identify early predictors of sunitinib cardiotoxicity.
Conditions Studied
Study Locations (1)
Pennsylvania
- Abramson Cancer Center, University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2011-04 |
| Est. Completion | 2017-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01370109
The ClinicalTrials.gov registry entry for NCT01370109 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Renal Cell Carcinoma 4 appearing as the primary indexed condition, and to 0 interventions.
NCT01370109 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01370109 about?
NCT01370109 is a clinical study titled "Cardiovascular Effects of Sunitinib Therapy (CREST)". Tyrosine kinase inhibitors such as sunitinib are used in the treatment of renal cell carcinoma and have significant off-target effects with cardiac toxicity and resultant ventricular cardiac dysfunction being a major concern. However, the mechanisms of these effects in humans remains poorly defined,...
What is the current status of trial NCT01370109?
This trial is currently completed. The enrollment target is 98 participants. The study started on 2011-04. Estimated completion is 2017-12-31.
What conditions does trial NCT01370109 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma 4.
Who is sponsoring clinical trial NCT01370109?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01370109 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.